Precigen Overview

  • Founded
  • 1998

Founded
  • Status
  • Public

  • Employees
  • 320

Employees
  • Stock Symbol
  • PGEN

Stock Symbol
  • Investments
  • 25

  • Share Price
  • $1.59

  • (As of Wednesday Closing)

Precigen General Information

Description

Precigen Inc is a biotechnology company that develops synthetic biology solutions. The company designs build and regulate gene programs. Its technologies are broadly applicable across a wide range of diverse end markets. Intrexon's business model is to commercialize its technologies through exclusive channel collaborations with collaborators that have specific industry expertise, development resources, and sales and marketing capabilities, in order to bring new and improved products and processes to market. Its reportable segments are Biopharmaceuticals; Exemplar, and Trans Ova. The company's collaborators provide compensation through technology access fees, royalties, milestones, and reimbursement of certain costs.

Contact Information

Formerly Known As
Intrexon Corporation, Genomatix, Intrexon
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
NAS
Primary Office
  • 20358 Seneca Meadows Parkway
  • Germantown, MD 20876
  • United States
+1 (301) 000-0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Precigen Stock Performance

(As of Wednesday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$1.59 $1.58 $1.12 - $4.19 $331M 208M 880K $0.12

Precigen Financials Summary

In Thousands,
USD
TTM 30-Sep-2022 FY 2021 31-Dec-2021 FY 2020 31-Dec-2020 FY 2019 31-Dec-2019
EV 533,786 845,918 1,998,514 1,045,910
Revenue 118,436 103,873 103,178 90,722
EBITDA (48,571) (65,890) (72,864) (141,327)
Net Income 25,459 (92,166) (170,521) (322,324)
Total Assets 259,245 359,856 314,587 455,763
Total Debt 91,049 194,204 182,283 232,666
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Precigen Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Precigen‘s full profile, request access.

Request a free trial

Precigen Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Precigen Inc is a biotechnology company that develops synthetic biology solutions. The company designs build and regulat
Drug Discovery
Germantown, MD
320 As of 2021
00000
000000000 00000

000000

d exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in rep
0000 000000000
San Diego, CA
00 As of 0000
00000
000000000 00000

000000

r incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ul
0000000000000
Saint-Herblain, France
000 As of 0000
00000
00000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Precigen Competitors (38)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
BioAtla Formerly VC-backed San Diego, CA 00 00000 000000000 00000
0000000 Formerly VC-backed Saint-Herblain, France 000 00000 00000000 00000
0000000 Formerly VC-backed La Jolla, CA 000 00000 00000000 00000
00000000 Venture Capital-Backed Berkeley, CA 000 0000 00000000000 0000
000000 Formerly VC-backed Emeryville, CA 0000 00.000 000000000 00.000
You’re viewing 5 of 38 competitors. Get the full list »

Precigen Patents

Precigen Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20220282282-A1 Buffer solutions for electroporation Pending 26-Feb-2021 000000000
US-20220220187-A1 Chimeric receptor therapy Pending 12-Jan-2021 000000000
US-20220023420-A1 Fusion constructs and methods of using thereof Pending 10-Jul-2020 0000000000000
AU-2020369454-A1 Lettuce with increased shelf life Pending 25-Oct-2019 0000000000
CA-3155977-A1 Lettuce with increased shelf life Pending 25-Oct-2019 C12N15/102
To view Precigen’s complete patent history, request access »

Precigen Executive Team (37)

Name Title Board Seat Contact Info
Helen Sabzevari Chief Executive Officer & Board Member
John McLean President, Intrexon Crop Protection
Harry Thomasian Jr. Chief Financial Officer, Finance & Chief Accounting Officer, Accounting
Brad Osbourne Chief Accounting Officer, Accounting & Vice President
Donald Lehr JD Chief Legal Officer, Legal
You’re viewing 5 of 37 executive team members. Get the full list »

Precigen Board Members (12)

Name Representing Role Since
Cesar Alvarez JD Self Board Member 000 0000
Dean Mitchell Self Board Member 000 0000
Fred Hassan Self Board Member 000 0000
Helen Sabzevari Precigen Chief Executive Officer & Board Member 000 0000
James Turley Self Board Member 000 0000
You’re viewing 5 of 12 board members. Get the full list »

Precigen Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Precigen Investments & Acquisitions (25)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
000000000 09-Nov-2017 0000 00000 00.00 Pharmaceuticals
000000 16-Jun-2017 0000000000 000.00 Pharmaceuticals 000000 00
000000 000000 27-Sep-2016 000000000 Biotechnology
00000000 000 04-Apr-2016 00000 0000 Drug Discovery 000000 00
Enviroflight 25-Feb-2016 Merger/Acquisition Other Agriculture 00000 000
You’re viewing 5 of 25 investments and acquisitions. Get the full list »

Precigen Subsidiaries (3)

Company Name Industry Location Founded
Codexis Laboratories Hungary Biotechnology Budapest, Hungary 2008
00000000 Biotechnology San Diego, CA 0000
000000 Other Agriculture Abingdon, United Kingdom 0000
To view Precigen’s complete subsidiaries history, request access »

Precigen Exits (8)

Company Name Exit Date Exit Type Exit Size Status Buyers
000000000 09-Nov-2017 0000 0000000000 00.00 Completed
  • 00000000
000000000000 25-Feb-2016 000000000000000000 Completed
  • 2 buyers
000000 00000000000 12-Jan-2016 00000 (0000000000) Completed
  • 2 buyers
00000000 000000000 20-Apr-2015 000000000000000000 000.00 Completed
  • 00000000
AmpliPhi Biosciences 27-Mar-2015 PIPE 0000 Completed
  • 7 buyers
You’re viewing 5 of 8 exits. Get the full list »